Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07277270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 7 months later Jul 13, 2026 → Feb 14, 2028
See other at-risk trials from GlaxoSmithKline

Record History

  1. Primary completion pushed from Jul 13, 2026 to Feb 14, 2028 Trial sites expanded: 6 → 22 locations · Completion pushed from Sep 29, 2028 to May 1, 2030 · Enrollment target: 84 to 83 · 2 more Show 5 more changesShow less
    • Trial sites expanded: 6 → 22 locations
    • Completion pushed from Sep 29, 2028 to May 1, 2030
    • Enrollment target: 84 to 83
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 3 of 10 entries
  2. Phase: Phase 1/2 to Phase 1 Trial status: Not Yet Recruiting to Recruiting · Enrollment target: 72 to 84 · Study sites: 0 to 6 · 1 morev2 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 72 to 84
    • Study sites: 0 to 6
    • Start date changed from estimate of Dec 8, 2025 to Dec 3, 2025
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
245 trials monitored
See 20 trials at risk
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.
Trial Details
NCT Number NCT07277270
Lead Sponsor GlaxoSmithKline
Conditions Neoplasms
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov